TrialAmerican journal of hematology2013

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.

Ali T Taher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.